Genetix Appoints new Finance Director
News Jan 13, 2006
Genetix Group plc has announced the appointment of Andrew Kellett, 37, as Finance Director with effect from 27th March 2006.
Mr Kellett will be taking-up the position vacated by Gary Corsi who, as previously notified, will be leaving the Company with effect from 31st January 2006.
Since February 2000, Mr Kellett has been with Quest Diagnostics Inc and is currently Finance Director, Europe & Global Controller; Clinical Trials & Pharmaceutical Business Development.
He qualified as a Chartered Accountant with Coopers & Lybrand in 1992 and has held senior financial positions with MDC Corporation Inc, General Cable plc and United Biscuits plc.
Mark Reid, CEO of Genetix said, "We are delighted to welcome Andrew to the Board. His experience with growing internationally based companies and recent exposure to the business needs of pharmaceutical companies will be of particular benefit to the executive team."
GlaxoSmithKline plc (GSK) has launched a five-year, $67 million collaboration with the San Francisco and Berkeley campuses of the University of California to build a state-of-the-art laboratory. The goal is to use CRISPR technologies to explore how genes cause disease and to rapidly accelerate the discovery of new drugs.